Skip to main content
. 2020 Jul 23;10:12348. doi: 10.1038/s41598-020-69366-4

Figure 2.

Figure 2

Representative images of abdominopelvic computed tomography and immunohistochemistry from one responder with gallbladder cancer (TPS = 80). (A) Baseline computed tomography scan. (B) Computed tomography scan after 3 cycles of pembrolizumab. (C) Computed tomography scan after 10 cycles of pembrolizumab. (D) PD-L1 immunohistochemistry showing high PD-L1 expression (20 × magnification).